Millennium CEO
Executive Summary
Novartis North American oncology operations head Deborah Dunsire will succeed Mark Levin as CEO of Millennium by Aug. 1. Levin, a Millennium co-founder, will become a member of the board. Dunsire has headed Novartis' North American oncology operations since 1997; over the last eight years, the U.S. business achieved a compounded annual growth rate of 25%. Dunsire plans to take a "fresh look" at the Millennium business and will develop a strategy aimed at helping the company meet its goal of non-GAAP profitability by 2006...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.